PLC Systems, Inc. is a medical device company developing innovative technologies for the cardiac and vascular markets. The company’s newest product, RenalGuard, has been developed to help prevent the onset of Contrast-Induced Nephropathy (CIN) in at-risk patients undergoing certain cardiac and vascular imaging procedures.
The company today announced that final results from the MYTHOS investigator-sponsored clinical trial in Italy have been published. The results appeared in the January 2012 issue of JACC-Cardiovascular Interventions, a peer-reviewed journal of the American College of Cardiology.
The results from this trial found that RenalGuard is superior to the current standard of care at reducing rates of CIN and in-hospital dialysis in at-risk patients undergoing various imaging procedures. Developing CIN can lead to a range of serious and potentially lethal outcomes in patients who already have compromised kidney function.
The trial covered 170 patients with chronic kidney disease who underwent elective or urgent percutaneous coronary interventions in Italy. The results showed that these patients who used RenalGuard and underwent imaging procedures developed CIN at a 74% lower rate and had fewer adverse events than those patients were treated with overnight hydration.
For more information about PLC Systems and its RenalGuard product, please visit the company’s website at www.plcmed.com
Let us hear your thoughts below: